BioInvent announces additional efficacy data from Phase 1/2 trial with BI-1206 in solid tumors, including one patient with long-lasting stable disease and another experiencing a partial response. The study is testing the novel anti-FcyRIIB antibody in combination with pembrolizumab for patients who have previously progressed on PD-1/PD-L1 immune checkpoint inhibitors. The results suggest that BI-1206 enhances and recovers the activity of pembrolizumab.
Keywords: BioInvent, phase 1/2 trial, BI-1206, solid tumors, pembrolizumab.
Additional sentences:
- BioInvent International AB is a biotech company focused on developing immune-modulatory antibodies for cancer immunotherapy.
- The Phase 1/2 trial involves treating patients with advanced solid tumors who had previously failed treatment with PD-1/PD-L1 immune checkpoint inhibitors.
- BioInvent plans to share more updates on the IV arm of the trial later this year.
- In addition to solid tumor trials, BioInvent also has ongoing clinical programs in hematological cancers using their F.I.R.S.T™ technology platform.